Create Account

One Health helps you track and understand your health simply.

Create Account

One Health helps you track and understand your health simply.

Beta 2 Fraction

Proteins & Electrophoresis

B2 fractionBeta-2 globulin fractionBeta-2 region

Review status

Currently under review

Pending specialist review and validation.

What it shows

The Beta 2 Fraction is one part of a serum protein electrophoresis test, which separates the proteins in your blood based on their size and charge. The beta-2 region mostly reflects proteins such as complement component C3 and beta-lipoprotein, along with smaller contributions from other proteins that migrate in the same area.

Laboratories report the beta-2 fraction as a concentration alongside the other fractions to show your overall protein pattern. This test is different from the beta-2 microglobulin test, which measures a single specific protein for other clinical reasons.

Why it matters

Changes in the beta-2 fraction can point to inflammation or immune system activity involving complement, higher blood lipids, certain liver or kidney conditions, or the presence of an abnormal protein that can sometimes migrate in the beta region. It is commonly ordered as part of a broader workup when your clinician is evaluating unexplained inflammation, nutritional status, or possible plasma cell disorders.

On its own, the beta-2 fraction does not diagnose a condition, but it adds important context to other tests. Your clinician may use it together with lipid studies, complement tests, liver and kidney panels, or more specific tests for abnormal proteins to understand what is driving a change.

Understanding your results

A higher beta-2 fraction can be seen with acute or chronic inflammation, some infections, higher LDL cholesterol, pregnancy, or with certain medications that increase acute-phase proteins or lipoproteins. A lower beta-2 fraction can be associated with increased complement use in autoimmune disease or with reduced protein production in severe liver disease or malnutrition.

Your provider will look at the overall electrophoresis pattern and your symptoms before deciding on next steps. If a result is outside the expected range or suggests an abnormal protein in the beta region, you may be asked to repeat the test, provide a fasting sample to reduce lipemic interference, or have follow-up studies such as immunofixation, serum free light chains, complement testing, or lipid panels.

Reference ranges

1.84.1 g/L
All sexes
0 days – 150 years

Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.

Factors that could impact Beta 2 Fraction

  • Specimen type

    Serum is preferred. Using plasma can introduce fibrinogen that forms a beta-region band and may complicate interpretation.

  • Lipemia and fasting

    Recent meals or elevated lipids can increase beta-lipoprotein, raising the beta-2 fraction. A fasting sample can reduce this interference.

  • Inflammation or infection

    Complement proteins are part of the acute-phase response. Active inflammation, infection, or tissue injury can elevate the beta-2 fraction.

  • Liver function and nutrition

    Severe liver disease or malnutrition can reduce protein synthesis, sometimes lowering proteins that contribute to the beta-2 fraction.

  • Medications and hormones

    Estrogens, pregnancy, and corticosteroids may increase lipoproteins or acute-phase reactants, while lipid-lowering drugs can reduce the beta-2 signal.

  • Autoimmune and kidney conditions

    Autoimmune activity can consume complement and lower beta-2. Some kidney diseases alter protein handling and may change the pattern.

2026

References

  1. McGill University Health Centre. (2007, June 18). Beta 2 Fraction (Task CD 1064681). Laboratory reference ranges.
  2. Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., Landgren, O., Paiva, B., Dispenzieri, A., Weiss, B., LeLeu, X., Zweegman, S., Lonial, S., Rosinol, L., Zamagni, E., ... Moreau, P. (2014). International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology, 15(12), e538–e548.
  3. Keren, D. F. (2003). Protein electrophoresis in clinical diagnosis. Chicago, IL: ASCP Press.
  4. Rifai, N., Horvath, A. R., & Wittwer, C. T. (Eds.). (2018). Tietz textbook of clinical chemistry and molecular diagnostics (6th ed.). St. Louis, MO: Elsevier.